INB-400 (IN8bio)

INB-400 is an allogeneic, genetically modified gamma-delta (γδ) T-cell therapy developed by IN8bio, Inc. using its proprietary DeltEx Drug-Resistant Immunotherapy (DRI) platform. The therapy is engineered to express the MGMT (O6-methylguanine-DNA methyltransferase) gene, which confers resistance to alkylating chemotherapies such as temozolomide (TMZ). This modification allows the T cells to be administered concurrently with standard-of-care chemotherapy for glioblastoma multiforme (GBM), ensuring that the immune cells remain active and capable of targeting tumor cells even while the patient is undergoing lymphodepleting treatment. INB-400 leverages the natural ability of γδ T cells to recognize and kill malignant cells without the need for MHC-matching, making it suitable for an off-the-shelf allogeneic application. In April 2023, it became the first genetically modified γδ T-cell therapy to receive FDA Orphan Drug Designation. Although clinical trials were paused in 2025 for resource optimization, early data indicated improvements in progression-free survival compared to standard-of-care.

Other names

allogeneic genetically modified gamma-delta T cellsDeltExDrug-Resistant ImmunotherapyDRI